The Life Sciences Report
Notable Quotes
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay More >
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >
"CYTX's ADRC product has been approved for breast reconstruction in Europe." (11/26/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Michael Hay More >
"We expect FDA approval in the near term—likely by the end of the year—for OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August More >
"BDSI is quite an interesting company; we expect Bunavail to be approved." (11/26/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Michael Hay More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Dendreon Corp.TICKER: DNDN:NASDAQ
|